Brief: Bioinvent And CASI Pharmaceuticals CTA Approval For Clinical Studies In China

BioInvent International AB

10/12/2021 12:06

Dec 10 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT AND CASI PHARMACEUTICALS ANNOUNCE CTA APPROVAL
FOR
CLINICAL STUDIES OF BI-1206 IN NHL IN CHINA
    * CTA IS FOR INITIATION OF TWO CLINICAL TRIALS OF
ANTI-FCYRIIB
ANTIBODY, BI-1206, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
IN CHINA.
    * STUDIES ARE EXPECTED TO START IN H1 2022

Source text for Eikon:  ID:nMFN89F8Rj 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))